Abstract
Genetic factors significantly influence the balance of coagulation and anticoagulation, yet many variants related to venous thromboembolism (VTE) remain unidentified. This study investigated potential molecular mechanisms and pathogenic mutations associated with VTE by integrating transcriptome-wide profiling with protein structure analysis. By analyzing gene expression datasets (GSE48000 and GSE19151) and performing whole-exome sequencing (WES) on a cohort of 25 VTE patients and 17 controls, researchers identified 232 differentially expressed genes (DEGs). Functional enrichment highlighted RNA catabolic processes and ribosome pathways. Notably, the HNMT gene (rs11558538) was identified as a major predisposing factor. Structural analysis revealed that the Thr105Ile mutation disrupts protein stability. Furthermore, drug screening identified several candidates, including Aspirin and Dabigatran, for potential VTE therapy.
Introduction
Venous Thromboembolism (VTE)—comprising deep-vein thrombosis and pulmonary embolism—is the third most common cardiovascular disease globally. While genetics account for roughly 50% of VTE risk, the "missing heritability" remains a challenge. Classic markers like Factor V Leiden do not explain all cases. This research aims to bridge this gap by identifying how specific mutations alter protein structures and contribute to VTE's molecular mechanism.
Methods
The study employed an integrated bioinformatics pipeline:
- Transcriptome Profiling: Analysis of public datasets (GSE48000, GSE19151) to identify DEGs.
- Functional Enrichment: GO and KEGG analysis to determine biological pathways.
- Whole-Exome Sequencing (WES): Performed on an in-house cohort (25 VTE patients, 17 controls) to identify pathogenic mutations.
- Protein Structural Analysis: Visualization of the HNMT Thr105Ile mutation using PyMOL and Swiss-Model.
- Molecular Docking: Simulation of drug interactions with the mutated protein using AutoDock.
Key Results
Transcriptomic and Mutational Landscape
The analysis identified 232 DEGs, with significant enrichment in ribosome pathways. WES identified 48 mutations, with the HNMT variant (rs11558538) showing the strongest association (adjusted P-value = $1.2 \times 10^{-9}$).
The Role of HNMT and Structural Disruption
HNMT (Histamine N-Methyltransferase) inactivates histamine in vascular tissues. The rs11558538 (Thr105Ile) mutation occurs in an alpha-helix, where it disrupts two stabilizing hydrogen bonds. This likely leads to loss of enzymatic function, higher histamine levels, and a vascular environment predisposed to inflammation and clotting.
Therapeutic Screening
Six candidate drugs were identified that could potentially target the HNMT pathway. Aspirin and Dabigatran showed strong docking profiles, with Dabigatran forming three stabilizing hydrogen bonds with residues Phe9, Tyr15, and Ser91 of the HNMT protein.
Conclusion
The results suggest that HNMT (rs11558538) is a potential target for the diagnosis and treatment of VTE. This integrated approach provides a deeper understanding of VTE pathogenesis and highlights new avenues for personalized medicine. Future work will focus on wet-lab validation of these findings and exploring the clinical utility of HNMT as a biomarker.
Summary updated